Welcome to Current TV
H1N1 Swine Flu Virus Patented by Medimmune Back in 2008
New York : According to Dr T Ott the Swine Flu patent is owned by none other than Medimmune who stands to profit around $151 million dollars from US taxpayers.
MedImmune, LLC, headquartered in Gaithersburg, Maryland, became a wholly owned subsidiary of AstraZeneca in 2007. Since being acquired, MedImmune has remained a Maryland-based biotechnology development enterprise.
It produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for $1.06 billion of its $1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004.
FluMist was approved for children two years of age and older in 2007, but initially was approved only for healthy people ages 5 to 49, a significant limitation because it eliminated a significant market -- the millions of young children who find injections objectionable. Sales of FluMist fell short of analysts' expectations for the first two years the drug was sold. FluMist was initially sold in a frozen form, which was difficult for doctors to store
According to MedImmune website they are making a signficant, rapid response with a vaccine to the H1N1 variant of influenza, known as Swine flu. In early June 2009 it won a Department of Health and Human Services (HHS) contract, worth $90m.
Under the contract with HHS, MedImmune will continue to make its seasonal FluMist vaccine and also develop a vaccine targeted specifically at the H1N1 virus MedImmune then won a second contract to test its nasal spray flu technology as a viable treatment for the H1N1.
And now according to Dr T Ott investigation Medimmune applied for and received the patient for Swine Flu Virus back in 2008.
But according to WHO "OFFICIALLY" H1N1 is created naturally and it's a new strain of influenza virus,first identified in April 2009.If so how could Medimmune get the patent for the same back in 2008 ?
In past we reported about how Baxter Files H1N1 Swine Flu Vaccine Patent a Year Ahead of Outbreak.
more from Community:
from the community